Welcome to our dedicated page for Virios Therapeutics SEC filings (Ticker: VIRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for the latest developments on Virios Therapeutics’ antiviral pipeline often starts with a single question: where in hundreds of SEC pages can I find the numbers and study updates that move the stock? On this page you’ll locate every Virios Therapeutics SEC filing explained simply, from the annual report 10-K that breaks down R&D spend to the 8-K material events explained when new clinical data emerges.
Our AI-powered summaries strip out jargon so understanding Virios Therapeutics SEC documents with AI feels natural. Need fast access to a Virios Therapeutics quarterly earnings report 10-Q filing? We highlight cash runway, trial costs, and variance from previous quarters. Tracking leadership confidence? Real-time alerts surface Virios Therapeutics Form 4 insider transactions the moment they hit EDGAR, letting you spot Virios Therapeutics executive stock transactions Form 4 before the market digests them.
Use cases professionals rely on include:
- Compare R&D burn across quarters with one-click Virios Therapeutics earnings report filing analysis.
- Review Virios Therapeutics proxy statement executive compensation to gauge alignment with shareholders.
- Dive into shelf registrations to understand dilution risk without wading through legal text.
Whether you’re assessing phase-two trial momentum or monitoring a Virios Therapeutics insider trading Form 4 transactions cluster, Stock Titan delivers comprehensive coverage: every 10-K, 10-Q, 8-K, S-1, and more, updated in real time. Investors, analysts, and healthcare professionals save hours while our expert analysis links each disclosure to the science that underpins Virios Therapeutics’ potential.
Dogwood Therapeutics, Inc. (VIRI) filed a Form S-8 to register 108,612 additional shares of common stock for issuance under its Amended and Restated 2020 Equity Incentive Plan. The new shares supplement prior S-8 registrations (Dec 21 2020 and Jun 22 2022) and follow Board authorization on Apr 17 2025 and shareholder approval on Jun 18 2025. Standard incorporation-by-reference, exhibits (legal opinion, auditor consent, plan document) and undertakings are included. The filing is an administrative step to ensure sufficient shares are available for employee equity awards and does not provide new financial results or strategic disclosures.
Dogwood Therapeutics held its Annual Meeting on June 18, 2025, where stockholders approved several key matters. The most significant development was the approval of Amendment No. 2 to the company's Equity Incentive Plan, which increased the share reserve by 108,612 shares to a total of 191,112 shares. This follows the company's 25-for-1 reverse stock split from October 2024.
At the meeting, which had a 48.22% quorum representing 921,595 shares, stockholders voted on three main items:
- Election of seven directors, including Abel De La Rosa, Greg Duncan, and other board members, all of whom were successfully elected
- Ratification of Forvis Mazars, LLP as independent auditor for FY2025, approved with 888,808 votes in favor
- Approval of the Equity Incentive Plan amendment, which passed with 275,020 votes in favor
The filing indicates Dogwood Therapeutics is an emerging growth company trading on the Nasdaq Capital Market under symbol DWTX.
Dogwood Therapeutics, Inc. (DWTX) filed a low-complexity Form 4 reporting insider activity by director Abel De La Rosa on 06/18/2025. The filing shows two identical grants of 210 non-qualified stock options each, for a combined total of 420 options.
Key terms of the options:
- Exercise price: $4.80 per share
- Vesting/first exercisable date: 06/18/2026
- Expiration date: 06/18/2035
- Ownership form: Direct
No common shares were bought or sold and no other derivative transactions were reported. After the grants, De La Rosa’s beneficial ownership consists solely of the 420 options. The transaction is coded “A” (acquisition) and was filed on 06/23/2025.